11 – 20 of 35
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Histological grade provides significant prognostic information in the discrimination between luminal A-like and luminal B-like HER-2 normal subtypes of breast cancer according to St Gallen 2013
(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
A novel model for Ki67 assessment in breast cancer.
(
- Contribution to journal › Article
-
Mark
The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer.
(
- Contribution to journal › Article
-
Mark
The role of histological grade in discrimination between Luminal A-like and Luminal B-like subtypes in a series of premenopausal breast cancer patients
2014) 26th European Congress of Pathology In Virchows Archiv: an international journal of pathology 465(Supplement 1). p.123-123(
- Contribution to journal › Published meeting abstract
-
Mark
Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor.
(
- Contribution to journal › Article
-
Mark
71p * statin-induced anti-proliferative effects via cyclin d1 and p27 in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P2-10-28: The Prognostic Index, KiGE, Combining Proliferation, Histological Grade and Estrogen Receptor Status Challenges Gene Profiling – A Study in 1,854 Chemo-Naïve Women with N0/N1 Primary Breast Cancer.
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.
(
- Contribution to journal › Article
-
Mark
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Article